Skip to main content
. 2014 Dec;11(4):270–276. doi: 10.7497/j.issn.2095-3941.2014.04.006

Figure 3.

Figure 3

Comparison of the different drug group’s EGFR-TKI initial treatment and retreatment in progression-free survival.